Posts by Mourabit Halima

Sacituzumab Tirumotecan (sac-TMT) is a novel TROP2-targeted ADC independently developed in China. Over the past two years, its clinical findings have been frequently presented at major international conferences and published in top-tier journals. At the 2025 ASCO Annual Meeting, Professor Yongmei Yin from Jiangsu Provincial People’s Hospital delivered a Rapid Oral Abstract presentation on the phase II OptiTROP-Breast05 study, which evaluated sac-TMT as a first-line therapy for advanced triple-negative breast cancer (TNBC). The results demonstrated impressive efficacy and a favorable safety profile. Oncology Frontier invited Professor Yongmei Yin at the conference to discuss the study's key outcomes and how sac-TMT, as a leading TROP2 ADC, is poised to make a lasting impact on breast cancer treatment in China and globally.

The therapeutic landscape in oncology is undergoing a profound shift with the rise of genome engineering technologies such as CRISPR/Cas9, base editing, and prime editing. These tools are enabling the…

Although published in 2023, the MAINTAIN trial remains a key reference in the evolving management of HR+/HER2− metastatic breast cancer following progression on CDK4/6 inhibitors.In this randomized, placebo-controlled phase II…

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. A Phase III randomized controlled trial (SYLT-021), led by Dr. Rongbo Lin’s team from the Department of Gastrointestinal Oncology, Fujian Cancer Hospital, was selected as one of six Proffered Paper oral presentations in the palliative care session. This study compared hydromorphone intravenous patient-controlled analgesia (IPCA) with oral morphine for severe cancer pain management.